{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ehlers JP"],"funding":["NEI NIH HHS","Novartis Pharmaceuticals Corp"],"pagination":["1204-1213"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8387490"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(12)"],"pubmed_abstract":["<h4>Purpose</h4>To assess longitudinally the effect of anti-vascular endothelial growth factor (VEGF) treatment on ellipsoid zone (EZ) integrity, subretinal hyperreflective material (SHRM), and the sub-retinal pigment epithelium (sub-RPE) compartment in eyes with neovascular age-related macular degeneration (nAMD).<h4>Design</h4>Post hoc analysis of the OSPREY clinical trial, a prospective, double-masked, phase 2 study comparing brolucizumab 6 mg with aflibercept 2 mg over 56 weeks.<h4>Participants</h4>Participants with treatment-naïve nAMD at the initiation of the trial were included in the analysis.<h4>Methods</h4>Eyes were evaluated with spectral-domain OCT at 4-week intervals in the OSPREY trial (n = 81). Spectral-domain OCT scans collected from each visit were segmented automatically "],"journal":["Ophthalmology. Retina"],"pubmed_title":["Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration."],"pmcid":["PMC8387490"],"funding_grant_id":["K23 EY022947","R34 EY029308"],"pubmed_authors":["Kaiser PK","Reese J","Le TK","Srivastava SK","Ehlers JP","Hu M","Heier JS","Brown DM","Meng X","Lunasco L","Zahid R"],"additional_accession":[]},"is_claimable":false,"name":"Longitudinal Assessment of Ellipsoid Zone Integrity, Subretinal Hyperreflective Material, and Subretinal Pigment Epithelium Disease in Neovascular Age-Related Macular Degeneration.","description":"<h4>Purpose</h4>To assess longitudinally the effect of anti-vascular endothelial growth factor (VEGF) treatment on ellipsoid zone (EZ) integrity, subretinal hyperreflective material (SHRM), and the sub-retinal pigment epithelium (sub-RPE) compartment in eyes with neovascular age-related macular degeneration (nAMD).<h4>Design</h4>Post hoc analysis of the OSPREY clinical trial, a prospective, double-masked, phase 2 study comparing brolucizumab 6 mg with aflibercept 2 mg over 56 weeks.<h4>Participants</h4>Participants with treatment-naïve nAMD at the initiation of the trial were included in the analysis.<h4>Methods</h4>Eyes were evaluated with spectral-domain OCT at 4-week intervals in the OSPREY trial (n = 81). Spectral-domain OCT scans collected from each visit were segmented automatically ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-04-19T15:40:02.729Z","creation":"2025-04-19T15:40:02.729Z"},"accession":"S-EPMC8387490","cross_references":{"pubmed":["33640493"],"doi":["10.1016/j.oret.2021.02.012"]}}